The role of interleukin-1 beta in the pathophysiology of Schnitzler's syndrome.

Abstract

INTRODUCTION:

Schnitzler's syndrome (SchS) is a disabling autoinflammatory disorder, characterized by a chronic urticarial rash, an M-protein, arthralgia, and other signs of systemic inflammation. Anti-interleukin-1 (IL-1) beta antibodies are highly effective, but the pathophysiology is still largely unknown. Here we studied the effect of in-vivo IL-1 inhibition on serum markers of inflammation and cellular immune responses.

METHODS:

Eight patients with SchS received monthly subcutaneous (s.c.) injections with 150 mg canakinumab for six months. Blood was drawn for measurement of serum markers of inflammation (12 times per patient) and for functional and phenotypic analysis of both freshly isolated and toll-like receptor (TLR)-ligand-stimulated peripheral blood mononuclear cells (PBMCs) (five times per patient). All data were compared to results of healthy controls.

RESULTS:

IL-6 levels in serum and in lysates of freshly isolated PBMCs and serum myeloid-related protein (MRP8)/14 and S100A12 levels correlated with disease activity. In vitro, LPS stimulation resulted in higher IL-6 and IL-1 beta production in PBMCs from symptomatic SchS patients compared to healthy controls, whereas patient cells were relatively hyporesponsive to poly:IC and Pam3Cys. The mRNA microarray of PBMCs showed distinct transcriptomes for controls, symptomatic patients and anti-IL-1-treated patients. Numbers of T- and B-cell subsets as well as M-protein concentrations were not affected by IL-1 inhibition. Free light chain levels were elevated in 4 out of 8 patients.

CONCLUSIONS:

In conclusion, patient PBMCs are hyperresponsive to LPS, and clinical efficacy of IL-1 beta inhibition in patients with SchS is associated with in-vivo and ex-vivo suppression of inflammation. Interestingly, patient PBMCs showed divergent responses to TLR2/6, TLR3 and TLR4 ligands. Our data underscore that IL-1 beta plays a pivotal role in SchS.

• Authors: Heleen D de Koning, Joost Schalkwijk, Monique Stoffels, Johanna Jongekrijg, Joannes F M Jacobs, Eugène Verwiel, Hans J P M Koenen, Frank Preijers, Dirk Holzinger, Irma Joosten, Jos W M van der Meer, Anna Simon
• Journal: Arthritis research & therapy (Arthritis Res Ther) Vol. 17 Pg. 187 (Jul 22 2015) ISSN: 1478-6362 [Electronic] England
• PMID: 26198339 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Biomarkers
• Interleukin-1beta
• canakinumab

Topics

• Antibodies, Monoclonal (pharmacology, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Biomarkers (blood)
• Cells, Cultured
• Female
• Humans
• Interleukin-1beta (antagonists & inhibitors, physiology)
• Leukocytes, Mononuclear (drug effects, metabolism)
• Male
• Schnitzler Syndrome (blood, diagnosis, drug therapy)